Animal models and therapeutic molecules

Patent metadata

Field	Value
Publication number	US-9896516-B2
Application number	US-201615095315-A
Country	US
Kind code	B2
Filing date	Apr 11, 2016
Priority date	Mar 28, 2012
Publication date	Feb 20, 2018
Grant date	Feb 20, 2018

Abstract

The invention discloses methods for the generation of chimaeric human—non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanized antibodies; compositions comprising these fully humanized antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in these methods.

First claim

We claim:

1. A mouse having a genome comprising a homozygous recombinant immunoglobulin light chain locus,
said homozygous recombinant immunoglobulin light chain locus comprising unrearranged human V light chain gene segments positioned (i) at an endogenous mouse immunoglobulin light chain locus comprising an endogenous light chain enhancer and (ii) upstream of a constant region,
said homozygous recombinant light chain locus being functional to rearrange to express an Ig light chain comprising a human V region,
wherein said homozygous recombinant immunoglobulin light chain locus comprises human Vλ gene segments and Jλ gene segments operatively linked to an endogenous kappa light chain enhancer at an endogenous kappa locus,
wherein said mouse expresses endogenous λ light chain,
wherein said mouse comprises B cells expressing an immunoglobulin chain comprising a human Vλ region and B cells comprising an immunoglobulin chain comprising an endogenous Vλ region, and among said human and endogenous Vλ regions, said human Vλ region predominates,
wherein at least 80% of the immunoglobulin light chains that comprise λ variable regions expressed in said mouse comprise human λ variable regions,
wherein said mouse comprises IgG comprising human Vλ region,
wherein said human Vλ and Jλ gene segments comprise at least the functional V and J gene segments from Vλ2-18 to Jλ7 of a human λ light chain locus.

2. The mouse of claim 1 , wherein said unrearranged human V light chain gene segments comprise a 3′ human V segment which is positioned within 100 kb of said endogenous light chain enhancer.

3. The mouse of claim 1 , wherein said endogenous light chain enhancer is in germline order relative to an endogenous constant region.

4. The mouse of claim 1 , wherein said endogenous kappa light chain enhancer comprises an iEκ or 3′ Eκ enhancer or both.

5. The mouse of claim 1 , wherein the recombinant immunoglobulin light chain locus comprising human Vλ gene segments and Jλ gene segments is positioned upstream of an endogenous constant kappa region.

6. The mouse of claim 1 , wherein said IgG comprising human Vλ regions comprises antigen specific human Vλ.

7. The mouse of claim 1 , wherein said IgG comprising human Vλ regions comprises a repertoire of human λ variable regions.

8. The mouse of claim 1 , wherein said mouse produces subsequent generation mice comprising unrearranged human Vλ and Jλ light chain gene segments positioned (i) at an endogenous mouse immunoglobulin light chain locus comprising an endogenous light chain enhancer and (ii) upstream of a constant region, said recombinant light chain locus being functional to rearrange to express an Ig light chain comprising a human Vλ region.

9. The mouse of claim 1 , wherein endogenous VK expression is inactive.

10. The mouse of claim 1 , wherein said mouse expresses λ immunoglobulin light chains comprising a plurality of a human λ variable regions encoded by a human Vλ and Jλ gene segments, and wherein said human Vλ gene segments comprise Vλ3 1, Vλ2-18, Vλ3-16, V2-14, Vλ3-12, Vλ2-11, Vλ3-10, Vλ3-9, Vλ2-8, and Vλ4-3; and wherein said human Vλ and Jλ gene segments are included in said human λ locus DNA.

11. A mouse having a genome comprising a homozygous recombinant immunoglobulin light chain locus,
said homozygous recombinant immunoglobulin light chain locus comprising unrearranged human V light chain gene segments positioned (i) at an endogenous mouse immunoglobulin light chain locus comprising an endogenous light chain enhancer and (ii) upstream of a constant region,
said homozygous recombinant light chain locus being functional to rearrange to express an Ig light chain comprising a human V region,
wherein said homozygous recombinant immunoglobulin light chain locus comprises human Vλ gene segments and Jλ gene segments operatively linked to an endogenous kappa light chain enhancer at an endogenous kappa locus,
wherein 80% of total splenic B cells comprise immunoglobulin light chains that comprise λ variable regions expressed in said mouse comprise human λ variable regions, and wherein said mouse comprises IgG comprising human Vλ,
wherein said human Vλ and Jλ gene segments comprise at least the functional V and J gene segments from Vλ2-18 to Cλ7 of a human λ light chain locus,
wherein said mouse expresses endogenous λ light chain;
wherein said mouse comprises B cells expressing an immunoglobulin chain comprising a human Vλ and B cells comprising an immunoglobulin chain comprising an endogenous Vλ, and among said human and endogenous Vλ said human Vλ predominates,
wherein the recombinant immunoglobulin light chain locus comprising human Vλ gene segments and Jλ gene segments is positioned upstream of an endogenous constant kappa region.

Assignees

• Kymab Ltd

Inventors

• Bradley Allan
• Lee E Chiang
• Liang Qi
• Wang Wei
• Spensberger Dominik
• Liu Hui
• Clube Jasper

Classifications

• C07K2317/51

  Complete heavy chain or Fd fragment, i.e. VH + CH1 · CPC title

• C12N15/8509

  for producing genetically modified animals, e.g. transgenic · CPC title

• C07K16/18

  against material from animals or humans · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• A01K2217/052

  inducing gain of function · CPC title